60 results
8-K
EX-99.1
APLS
Apellis Pharmaceuticals Inc
27 Feb 24
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
7:30am
were partially offset by an increase in compensation and related personnel costs.
General and Administrative (G&A) Expenses.
G&A expenses were $141.7
8-K
EX-99.1
6wv 9q9keyfsrj
31 Jul 23
Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results
8:03am
424B5
fz2zrzu2w82dyqc
24 Mar 22
Prospectus supplement for primary offering
8:02pm
424B5
xrow 5n96884gsve7i7c
23 Mar 22
Prospectus supplement for primary offering
5:14pm
424B5
t14oqvt0pif j96ca
17 Nov 21
Prospectus supplement for primary offering
9:02am
424B5
sk6vna2x22kcxlg9h
15 Nov 21
Prospectus supplement for primary offering
5:24pm